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ABSTRACT 
Objective: Lunasin peptide, with its chemopreventive and chemotherapeutic abilities, is known to affect carcinogenesis via epigenetic regulation 
involving histone acetylation. This study investigated lunasin, which can be found in soy, and its effects towards histone deacetylase (HDAC] 
expression in a mouse model of carcinogenesis. 
Methods: Thirty Swiss Webster mice were grouped into normal, positive control, negative control, and experimental groups. Except for the normal 
group, mice underwent carcinogenesis induction through azoxymethane (AOM] and dextran sodium sulfate (DSS] injection. Experimental mice 
received lunasin-enriched soy extract at a dosage of 250 mg/kg BW (kilogram body weight), 300 mg/kg BW, and 350 mg/kg BW for 4 w. Distal 
colon samples were stained by using immunohistochemistry (IHC]. HDAC expression was measured by IHC optical density score.  
Results: Average HDAC expression was 202.4% in the normal group, 239.3% in the negative control, 175.25% in the positive control, 202.03% at 
250 mg/kg BW dose, 219.53% at 300 mg/kg, and 166.68% at 350 mg/kg BW. There was no significant difference between HDAC expression at 250 
mg/kg BW and 300 mg/kg BW soy extract. However, at 350 mg/kg BW soy extract there were significant changes in HDAC expression.  
Conclusion: lunasin in soy extract at a 350 mg/kg BW dose can decrease HDAC expression in a colorectal cancer carcinogenesis model. 
Keywords: Colorectal cancer, Epigenetics, Histone deacetylase enzyme, Lunasin, Soy 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ijap.2019.v11s6.33571 
 
INTRODUCTION 
Globally, colorectal cancer is the third most prevalent cancer in men, 
with 746,000 cases diagnosed annually, and the second most 
prevalent in women (614,000 cases). Approximately 55% of 
colorectal cancer cases occur in developing countries [1]. In 
Indonesia, colorectal cancer incidence is 12.8 cases for every 
100,000 adults [2]. Colorectal cancer is the fourth highest cause of 
mortality with almost 700,000 deaths in 2012, and the third most 
frequently diagnosed malignancy, with annual new cases totaling 
around 1.4 million. It is estimated that global colorectal cancer 
burden will increase by approximately 60% to 2.2 million new cases 
and 1.1 million deaths by 2030 [3]. 
There are multiple options for colorectal cancer treatment. If the 
cancer is resectable, surgery and radiofrequency ablation can be 
undertaken alongside cytotoxic therapies such as radiation and 
chemotherapy, as well as other alternatives such as immunotherapy. 
However, the majority of colorectal cancer cases cannot be resected 
and radiofrequency ablation has a high rate of local tumor 
recurrence. Moreover, radiation and chemotherapy have a low 
therapeutic index, high toxicity, and various side effects. 
Inflammation involving multiple immune cells is associated with 
tumorigenesis and is thus a target of immunotherapy, but this 
modality is still associated with toxicity. Innovative strategies in 
adjuvant therapy to improve the effects of conventional therapies 
are still required [4-6]. 
Other therapeutic options currently being researched are nutritional 
therapies. Soy consumption is associated with a reduction in cancer 
risk of approximately 21% in women [7]. Soy contains a protein 
called lunasin, which consists of 43 amino acids.[8] A study by Mejia 
et al. found that lunasin concentrations in tested substances 
including soy flour and soy protein concentrate varied between 0.1–
1.33 g/100 g of flour [9]. Multiple studies have demonstrated that 
lunasin has a chemopreventive capability by inhibiting cell 
transformation and increasing chemotherapeutic response in 
various cancer types [10]. In HT-29 colon cancer cells, lunasin can 
induce apoptosis through the mitochondrial pathway and pro-
apoptotic clusterin expression [11]. Its sensitivity has been shown in 
animal models of lung cancer and melanoma, and is thought to relate 
to integrin signaling and histone acetylation changes. In colorectal 
cancer cells, lunasin has cytotoxic effects associated with integrin 
expression and is suggested to have the potential to prevent 
metastasis. Lunasin also has epigenetic mechanisms by inhibiting H3 
and H4 histone acetylation and functioning as a tumor suppressor 
[12-14]. Studies have shown that lunasin can affect cancer through 
multiple mechanisms, but research regarding the effects of lunasin 
on cell acetylation changes in colon cancer have yet to be performed. 
Based on the current challenges in colorectal cancer therapies and the 
lunasin research undertaken to date, this study aimed to determine 
whether lunasin-enriched soy extract can induce changes in histone 
deacetylase (HDAC) expression in an animal model of colon cancer 
induced by azoxymethane (AOM) and dextran sodium sulfate (DSS). It 
is hoped that lunasin has the potential to increase the efficacy of 
colorectal cancer therapy. Data obtained from this study can be used 
for further research of lunasin effects in colon cancer.  
MATERIALS AND METHODS 
Research animals 
Swiss Webster mice were obtained from the Animal Laboratory of 
Research and Development, Department of Health Ministry, Jakarta. 
Thirty-one male mice of±25 g weight and±12 w of age were used. 
Using the Federer formula, the minimum number of mice was 
calculated to be 24. Mice were sampled randomly and divided into six 
groups: normal, negative control, positive control, and 250 mg/kg BW, 
300 mg/kg BW, and 350 kgBW of lunasin-enriched soy extract. 
Soy extraction and lunasin analysis 
The Grobogan variety of soy from Bogor, Indonesia underwent a 
pressing process for 30 min at 100–150 atm pressure and 50 °C to 
separate the oil. The resulting material was blended to soy flour. A 
total of 1250 g of the flour was macerated for 60 min in 6250 ml of 
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phosphate buffer saline (PBS). The maceration solute was filtered 
three times with filtration paper, and the filtrate was dried in an 
evaporator at 50 °C, resulting in a dry extract. The quantity of 
lunasin in the extract was analyzed by high-performance liquid 
chromatographic (HPLC) using a WatersXBridge TM C from Agilent 
Technologies at 18.5 µm with a UV detector a and column of 4.6 × 
150 mm in diameter. 
Mouse experiments 
Mice underwent adaptation for one week in the laboratory prior to the 
start of the experiments. The physical health of the mice was 
confirmed before carcinogenesis induction. Mouse experiments were 
performed according to the Guide for the Care and Use of Laboratory 
Animals and the Animal Care and Use Committee. Mice received ad 
libitum standard food and drink and were maintained in a 12h 
light/dark cycle at a controlled temperature of 25oC at 55% humidity. 
The carcinogenesis induction protocol was adapted from Kusmardi 
et al. [15] Mice received azoxymethane (AOM) diluted in 0.9% NaCl 
through intraperitoneal (ip) injection of a single dose of 10 mg/kg 
BW in the first week of the experiment; the normal group received 
an injection of 0.9% NaCl. One week after AOM administration, mice 
received food and drink containing 2% dextran sodium sulfate (DSS) 
daily for a week. 
After carcinogenesis induction with AOM+DSS, mice were divided 
into six groups and treated accordingly for four weeks. The normal 
and negative control group received 0.9% NaCl, the positive control 
group received 150 mg/kg BW aspirin, and the experimental group 
received oral lunasin therapy with 250 mg/kg BW, 300 mg/kg BW, 
or 350 mg/kg BW of soy extract. The process of carcinogenesis 
induction followed by administration of lunasin therapy was 
conducted over a total of six weeks. Mice were anesthetized with 
75–100 mg/kg of ketamine and 10 mg/kg xylazine with a 23–25 G 
syringe and needle, and then killed by neck dislocation and colon 
tissue was excised. The tissue was washed in water and fixed with 
10% formalin before embedding in paraffin medium. Sections of 4 
µm thickness were then cut. Immunohistochemistry (IHC) with 
primary anti-HDAC antibody was undertaken and sections were 
counterstained with hematoxylin-eosin. 
 
 




Fig. 2: IHC of mouse distal colon. Arrows indicate HDAC expressionKruskal Wallis test revealed there were statistically significant 
differences between two or more groups (P=0.031), table 2 shows the P-values of mann whitney test between the groups, and fig. 2 details 
the median, minimum, and maximum values of HDAC expression, revealing a significant differences between the groups 
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Slides were observed at ×400 by light microscopy (Leica and 
Olympus). Each slide was imaged in five random visual fields. Total 
positive cell count (brown color) and negative cell count (blue color) 
were obtained with Image J software. Cells with positive staining in 
the nucleus and/or cytoplasm were marked with a dark blue dot for 
high positivity, a light blue dot for moderate positivity, and a green 
dot for weak positivity. Negative cells were marked with a purple 
dot. Cell count results are shown as a percentage based on IHC 
optical density score. [16] 
100 
HP, high positivity; MP, moderate positivity; WP, week positivity; N 
Negative 
Statistical analysis 
Data were analyzed using SPSS (Statistical Package for Social Sciences) 
for Mac 24.0 version. Kruskal Wallis non-parametric test followed by 
Mann Whitney test was applied to identify differences between two 
groups. Significant differences are indicated at P-values of<0.05. 
RESULTS 
HDAC expression was quantified as a percentage. Based on the 
Shapiro-Wilk normality test, data distribution was not normal 
(P=0.005). HDAC expression is shown as median, minimum, and 
maximum values in table 1. 
 
Table 1: Median, minimum, and maximum values of HDAC expression 
Group n Median (Minimum-Maximum) 
Normal 4 180,645 (156,44–183,21) 
Negative control 5 217,200 (197,88–318,55) 
Positive control 4 163,605 (149,03–224,76) 
250 mg/kgBW dose 4 200,000 (187,89–220,23) 
300 mg/kgBW dose 5 184,86 (159,04–292,61) 
350 mg/kgBW dose 4 165,250 (147,02–189,21) 
IHC of mouse distal colon epithelial cells is shown in fig. 2. Morphological changes and high HDAC expression were observed in the negative control group. 
 
Table 2: Mann-whitney post-hoc test results p value 
Group N NC PC D250 D300 D350 
1. N -      
2. NC 0,014* -     
3. PC 0,386 0,086 -    
4. D250 0,021* 0,221 0,248 -   
5. D300 0,086 0,347 0,142 0,624 -  
6. D350 0,564 0,014* 0,773 0,043* 0,142 - 
*P<0.05; N, normal, NC, negative control, NP, positive control; D250, 250 mg/kg BW; D300, 300 mg/kg BW; D350, 350 mg/kg BW. 
 
 
Fig. 2: Median, minimum, and maximum values of HDAC expression. *P<0.05 
 
DISCUSSION 
Class 1 HDAC enzymes, such as HDAC1, HDAC 2, HDAC 3, and HDAC 
8, and class 2 HDAC enzymes such as HDAC 4 are found in the 
normal colon and intestine, especially in proliferating crypts. The 
abundance of HDAC expression in crypts is consistent with the role 
of HDACs in maintaining cell proliferation and survival and 
inhibiting differentiation [17]. This study used an animal model to 
study the effects of lunasin-enriched soy extract in colorectal cancer. 
We chose male Swiss Webster mice because of their size and 
practicality. Male mice were chosen to eliminate the effects of the 
estrous cycle and to obtain more homogenous data. 
In this study, HDAC expression was demonstrated by IHC staining. 
Brown staining indicated HDAC expression and blue counterstaining 
was undertaken with hematoxylin-eosin. The highest levels of HDAC 
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expression were observed in the negative control group, and the 
lowest levels were identified in the group that received 350 mg/kg 
BW soy extract. HDAC expression decreased with increases in soy 
extract dose, as demonstrated by stronger brown staining in tissue 
that was exposed to low doses of soy extract. Besides the negative 
control and experimental groups, the normal and positive control 
groups also expressed HDAC. Morphological changes such as 
hyperplasia were identified in the negative control group, but not in 
the positive control group. 
Cancer induction in mice using azoxymethane (AOM) and dextran 
sodium sulfate (DSS) was successful, but with significant differences 
between the normal and negative control groups. Both agents work 
synergistically to initiate carcinogenesis in mice. As its 1,2 
dimethylhydrazine (DMH) metabolite, AOM is a carcinogenic 
substance with high potency and good stability. After metabolization 
in the body, AOM is catalyzed to the mutagenic agent 
methylazoxymethanol (MAM), which can function through various 
signaling pathways such as TGF-β, β-catenin, and K-RAS. The 
inflammatory agent DSS shortens latency time in in colorectal cancer 
induction in a dose-dependent manner. Inflammation has been 
known to be related to cancer, and DSS is a nongenotoxic 
carcinogen. In colorectal cancer, risk increases with the degree of 
inflammation and disease duration [18]. 
HDAC expression between the normal and positive control groups 
was not statistically significant, and the average expression in the 
positive control group was lower compared with the normal group. 
In normal colon tissue, HDAC enzyme was expressed but expression 
increased during carcinogenesis. Treatment with lunasin-enriched 
soy extract resulted in lower HDAC expression in the positive 
control group compared with the normal group, but this decrease 
was not statistically significant. 
There was no significant difference between the positive control group 
and the negative control group. In an in vivo study in mice, Guo et al. 
observed that 0.02% aspirin in AOM/DSS-induced mice was capable of 
downregulating HDAC protein expression and activity. It also lowered 
acetylation levels at histone H3 lysine 27. Aspirin is thought to exerti 
its effects through an epigenetic mechanism, but further research is 
required to understand the mechanism by which aspirin modifies 
histone acetylation and HDAC activity [19]. Meanwhile, an in vitro 
study by Sonnemann et al. in ovarian cancer cells revealed that aspirin 
had no effect on histone acetylation regardless of whether HDAC 
inhibitor was present. They found no significant changes in HDAC 
expression following administration of aspirin in an animal model of 
colorectal cancer carcinogenesis [20]. Compared with the study by 
Guo et al. using 0.02% aspirin, Sonnemann et al. used a dose of 0.015% 
[19]. Thus, aspirin levels may not be enough to induce significant 
differences in HDAC expression. 
Lunasin-enriched soy extract was obtained from the Grobogan variety 
of soy. Grobogan was chosen because it matures faster than other 
varieties, with larger beans of 18 g/100 beans, and has a high protein 
content [21]. In Indonesia, soy is easily obtained and is consumed by 
much of the population in a variety of ways. Lunasin content in 
Grobogan soy extract was analyzed by HPLC and the concentration of 
lunasin was found to be 0.838 mg/g soy extract. Hernandez-Ledesma 
et al. found that, compared with other plants such barley, wheat and 
rye, soy (Glycine max) had the highest lunasin content, with 
concentrations ranging 0.5–8.1 mg/g [22]. In soy, protein 
concentration is related to nutrient distribution. Soy with low protein 
content contains high amounts of isoflavone and saponin, but lower 
levels of minerals and bioactive peptides such as lunasin [23]. 
To observe the effects of lunasin-enriched soy extract in mice with 
colorectal cancer, the experimental groups were compared with a 
negative control group. Significant differences were identified at the 
highest dose of 350 mg/kg BW. Expression of HDAC at 250 mg/kg 
BW and 300 mg/kg BW was not significant. A dosage of 350 mg/kg 
BW soy extract significantly reduced HDAC expression but this was 
not found at lower doses. Upregulation of HDAC is associated with 
abnormal histone acetylation, which causes dysfunctional gene 
transcription regulation during cancer progression. Decreases in 
histone acetylation have been implicated in colorectal cancer, such 
as H3ac, H4ac, H4K16ac, and H3K18ac [24]. 
Further research using doses higher than 350 mg/kg BW is required 
to determine whether decreases in HDAC expression results in dose-
dependent effects and whether these changes are linear. To date, 
there are no other studies comparing lunasin with HDAC expression 
in colorectal cancer, and thus the dose and observed effects of 
lunasin cannot be compared. 
Statistical analysis revealed significant differences between the 
experimental groups at 250 mg/kg BW and 350 mg/kg BW. The 
group that received 300 mg/kg BW dose did not demonstrate 
significant changes in HDAC expression compared with 250 mg/kg 
BW and 350 mg/kg BW. This could infer that the dose difference 
between 250 mg/kg BW and 350 mg/kg BW was sufficient, but that 
the 300 mg/kg BW dose was too close to the doses of 250 and 350 
mg/kg BW. Future research should use larger intervals between the 
doses in experimental groups. 
Lunasin has epigenetic roles in disrupting cancer formation. The 
protein goes into the cell nucleus and competes with histone 
acetylase (HAT) enzyme to bind the deacetylated core of histones H3 
and H4. Inhibition levels of lunasin correlates with its concentration. 
The affinity of lunasin towards hypoacetylated chromatin and its 
inhibitory effect towards histone acetylation is explained by the 
E1A–Rb–HDAC model. Lunasin kills cell undergoing selective 
changes by interfering with histone acetylation–deacetylation 
dynamics during cell transformation. Tumor suppressor protein, Rb, 
interacts with E2F promoter to recruit HDAC, maintaining 
deacetylation of the histone core. When oncoprotein E1A releases 
the binding between Rb and HDAC, the deacetylated histone core is 
exposed to acetylation by HAT. This initiates lunasin, which 
competes with HATs such as P300/CBP-associated factor (PCAF) 
and yeast transcriptional coactivator GCN5 (yGCN5) to stop 
transcription and halt cell cycle progression. Disruption in the 
acetylation–deacetylation balance is perceived as abnormal by cells, 
causing apoptosis. 
The mechanism of lunasin competition with HAT is not fully 
understood. It is thought that the inhibitory effect of lunasin 
involves ionic binding of lunasin with negatively charged poly-D in 
deacetylated histones [8, 22, 25]. 
CONCLUSION 
Administration of lunasin-enriched soy extract at 350 mg/kg BW can 
significantly lower HDAC expression in a colorectal carcinogenesis 
animal model. Further studies using higher lunasin concentrations and 
a larger dosing range are required to verify whether lunasin exerts 
dose-dependent effects and if these effects are linear. 
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